CALR and myeloproliferative neoplasm: After blockade of both immune checkpoint molecules ex vivo and an increased T-cell reactivity, they also applied immune checkpoint blockade (ICB) in patients with monoclonal antibodies which restored the specific T-cell response at least in some CALR-mutant MPN patients.